

References – Pulmozyme

1. Welbanks L, editor. Compendium of Pharmaceuticals and Specialties, 37th Edition. Canadian Pharmacists Association, 2002, Ottawa.
2. Suri R, et al. Comparison of hypertonic saline and alternate day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomized trial. *Lancet* 2001;358:1316-21.
3. Cramer GW, Bosso JA. The role of dornase alfa in the treatment of cystic fibrosis. *Ann Pharmacol* 1996;30:656-61.
4. Witt DM, Anderson L. Dornase alfa: a new option in the management of cystic fibrosis. *Pharmacotherapy* 1996;16(1):40-8.
5. Kearney CE, Wallis CE. Deoxyribonuclease for cystic fibrosis. *The Cochrane Library* 2002 (Issue 2).
6. Perras C, Otten N. Pulmozyme: Clinical; and economic impacts. Technology overview. Canadian Coordination Office of Health Technology Assessment 1996; issue 1:1-8.
7. Quan JM, et al. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. *J Pediatr* 2001;139:813-20.
8. Coates AL. What is the cystic fibrosis clinician suppose to do with human recombinant dornase alfa? *J Pediatr* 201;139:768-70.
9. Duijvestijn YCM, Brand PLP. Systematic review of N-acetylcystine in cystic fibrosis. *Acta Pediatr* 1999;88:38-41.